Cantor Fitzgerald Remains a Buy on Septerna, Inc. (SEPN)

Business Insider

18-05-2025

Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Septerna, Inc. (SEPN – Research Report) on May 15 and set a price target of $25.00. The company's shares closed yesterday at $9.84.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Schimmer is a 5-star analyst with an average return of 11.0% and a 48.74% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, BridgeBio Pharma, and Aardvark Therapeutics, Inc..
In addition to Cantor Fitzgerald, Septerna, Inc. also received a Buy from TD Cowen's Yaron Werber in a report issued on May 15. However, yesterday, Wells Fargo maintained a Hold rating on Septerna, Inc. (NASDAQ: SEPN).
Based on Septerna, Inc.'s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $219 thousand and a GAAP net loss of $21.48 million. In comparison, last year the company earned a revenue of $118 thousand and had a net profit of $34.89 million
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SEPN in relation to earlier this year. Most recently, in March 2025, Ezekowitz Alan, a Director at SEPN bought 13,319.00 shares for a total of $92,167.48.